ALKBH5 and ovarian carcinoma: Furthermore, m6A erasers ALKBH5 promote ovarian cancer invasion, lymph node metastasis, and cisplatin resistance by regulating EMT, FAK, and JAK2/STAT3 signaling pathways (Sun et al., 2023[222]; Xu et al., 2024[307]; Nie et al., 2021[178]).